Business Wire

VA-VIRTUSTREAM

9.9.2020 13:02:12 CEST | Business Wire | Press release

Share
New Start/Stop Automation Available for Mission-Critical SAP® Applications Running on Virtustream Enterprise Cloud

Virtustream , an enterprise-class cloud company and Dell Technologies business, announced the availability of new start/stop automation for SAP® software landscapes and systems to help enterprises optimize their costs and controls through new self-service tools and step-by-step status updates. The functionality is now available in the Virtustream Enterprise Cloud via the xStream portal .

“Virtustream consistently drives new innovation into its Virtustream Enterprise Cloud platform to meet our demanding requirements and evolving mission-critical needs in the cloud,” says Ettore Tenaglia, Head of Service Operations, Almaviva. “The new automated features and tools help to improve our oversight, management and controls of our SAP environments, allowing us to optimize our processes to save valuable time and costs which can go back into our business.”

Address Compute Costs with Workload Automation

Virtustream’s new automated services reduce the amount of time and manual effort required from an organization’s internal IT team to perform start/stop commands on SAP landscapes and systems. The new tools and features include:

  • Strategic Scheduling: Start/stop operations can be scheduled through the Virtustream xStream portal in 30-minute windows on a one-time, on-demand, or recurring basis (daily, weekly or free-form). Additionally, users can set an expiration date for the agentless operation. Creating customized schedules to power virtual machines on or off helps to reduce compute costs. Additionally, automatically shutting down applications when they aren’t being used, such as during weekends and maintenance periods, can further optimize costs.
  • Defined Prioritization: Customers can assign each SAP system a set priority, allowing them to stagger the start/stop of their system so they proceed in a defined order, helping to ensure applications run efficiently and correctly.
  • Improved Access Control: Only approved administrators or users can access and use the start/stop automation, as dictated by the enterprise’s permission controls within their xStream tenant.
  • New Status Updates, Customized Notifications and Action Logs: A new status bar indicates the step-by-step process of each action as it progresses through the SAP system or landscape. Additionally, customized email notifications can be sent to each administrator based on actions (all actions or only scheduled) or by result (all results or failed only). An action log is generated for each system that shows all actions run on a specific SAP system or landscape including who initiated the action, when it was completed, and what actions were taken.

“Automation is key to streamlining IT operations and increasing cloud agility while freeing internal resources to focus on higher-priority projects or initiatives,” says Mike Zolla, Vice President of Cloud Platform Engineering and Delivery, Virtustream. “By extending automation deeper into our mission-critical Virtustream Enterprise Cloud platform, we are helping our enterprise customers increase the economic and business benefits of their SAP applications.”

Backed by Virtustream’s extensive experience migrating, optimizing and managing SAP workloads in the cloud, Virtustream’s new start/stop automation capability is available across all xStream-supported databases. Virtustream’s xStream Management Platform provides a powerful cloud management platform with a single interface across complex, distributed IT environments. xStream delivers economic and business benefits for a broad range of mission-critical enterprise applications in the cloud.

About Virtustream

Virtustream LLC, a Dell Technologies business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies, Virtustream’s xStreamCare professional and managed services, and the xStream® Management Platform and Infrastructure-as-a-Service (IaaS) meet the security, compliance, performance, efficiency, and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.

Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye